Skip to main content


  • Research
  • Open Access

Rice bran derivatives alleviate microglia activation: possible involvement of MAPK pathway

Journal of Neuroinflammation201613:148

  • Received: 17 January 2016
  • Accepted: 7 June 2016
  • Published:



Hyperactivation of microglia is considered to be a key hallmark of brain inflammation and plays a critical role in regulating neuroinflammatory events. Neuroinflammatory responses in microglia represent one of the major risk factors for various neurodegenerative diseases. One of the strategies to protect the brain and slow down the progression of these neurodegenerative diseases is by consuming diet enriched in anti-oxidants and polyphenols. Therefore, the present study aimed to evaluate the anti-inflammatory effects of rice bran extract (RBE), one of the rich sources of vitamin E forms (tocopherols and tocotrienols) and gamma-oryzanols, in primary rat microglia.


The vitamin E profile of the RBE was quantified by high-performance liquid chromatography (HPLC). Microglia were stimulated with lipopolysaccharide (LPS) in the presence or absence of RBE. Release of prostaglandins (prostaglandin (PG) E2, 8-iso-prostaglandin F (8-iso-PGF)) were determined with enzyme immunoassay (EIA). Protein levels and genes related to PGE2 synthesis (Cyclooxygenase-2 (COX-2), microsomal prostaglandin E synthase-1 (mPGES-1)) and various pro- and anti-inflammatory cytokines (TNF-α, IL-1β, IL-6, and IL-10), were assessed by western blot, ELISA, and quantitative real-time PCR. Furthermore, to elucidate the molecular targets of RBE, the phosphorylated state of various mitogen-activated protein kinase (MAPK) signaling molecules (p38 MAPK, ERK 1/2, and JNK) and activation of NF-kB pathway was studied.


RBE significantly inhibited the release of PGE2 and free radical formation (8-iso-PGF) in LPS-activated primary microglia. Inhibition of PGE2 by RBE was dependent on reduced COX-2 and mPGES-1 immunoreactivity in microglia. Interestingly, treatment of activated microglia with RBE further enhanced the gene expression of the microglial M2 marker IL-10 and reduced the expression of pro-inflammatory M1 markers (TNF-α, IL-1β). Further mechanistic studies showed that RBE inhibits microglial activation by interfering with important steps of MAPK signaling pathway. Additionally, microglia activation with LPS leads to IkB-α degradation which was not affected by the pre-treatment of RBE.


Taken together, our data demonstrate that RBE is able to affect microglial activation by interfering in important inflammatory pathway. These in vitro findings further demonstrate the potential value of RBE as a nutraceutical for the prevention of microglial dysfunction related to neuroinflammatory diseases, including Alzheimer’s disease.


  • Microglia activation
  • Neurodegeneration
  • Rice bran extract
  • Prostaglandins
  • Cytokines
  • Isoprostane


Neuroinflammation is one of the critical events in the progression of various neurodegenerative disorders such as multiple sclerosis (MS), Parkinson’s disease (PD), amyotrophic lateral sclerosis (ALS), and Alzheimer’s disease (AD) [14]. The main cell types responsible for the enhanced inflammation in various CNS pathologies are glial cells. Among them, activated microglia are principally involved in the maintenance and progression of neuroinflammation [5]. Microglia are resident immune cells in CNS and regarded as the primary component of the brain immune system. Under physiological conditions, these cells are constantly engaged in scanning their microenvironment for any exogenous or endogenous signals in efforts to maintain the homeostasis [6]. Infection, traumatic injury, ischemia, neurodegenerative diseases, or any altered neuronal activity indicating a potential threat to CNS can evoke profound changes in the microglial morphology and function [5, 79]. Under activated state, microglia is known to release a variety of cytotoxic mediators such as reactive oxygen species (ROS), pro-inflammatory cytokines, adenosine triphosphate (ATP), and arachidonic acid (AA) derivatives [1013]. These over-released mediators further exert their toxic effects on the healthy neurons and result in a vicious and self-propagating cycle of neuronal death [14]. Therefore, microglial activation-associated inflammation serves as an important model for investigating potential therapeutic entities for slowing the progression of neuronal cell death in neurodegenerative disorders.

Prostaglandin E2 (PGE2) is AA derivative, the production of which is catalyzed by the cyclooxygenases and prostaglandin (PG) E synthases (PGESs) enzymes. Cyclooxygenases exist in two subtypes, cyclooxygenase-1 (COX-1) and cyclooxygenase-2 (COX-2). COX-2 has been shown to be overexpressed by bacterial cell wall component lipopolysaccharide (LPS) in cultured microglia [15]. The final step in the synthesis of PGE2 is regulated by PGESs. To date, three PGESs have been characterized: the microsomal PGESs (microsomal prostaglandin E synthase-1 (mPGES-1) and mPGES-2) and the cytosolic PGES (cPGES) [16, 17]. Among these, mPGES-1 is an inducible enzyme, and it has been shown to be upregulated in activated microglia [18]. These enzymes are regulated by a variety of intracellular signaling molecules such as nuclear factor-kappa B (NF-kB) and mitogen-activated protein kinases (MAPK). NF-kB is a transcription factor, and it has been shown to be a central regulator of inflammatory response. MAPKs are a family of serine/threonine protein kinases which are critical for the production of inflammatory mediators. Some of the main kinases in this group include extracellular signal-regulated kinases (ERK 1/2), c-Jun N-terminal kinase (JNK) and p38 isoforms. In particular, increased activity of p38 MAPK has been closely associated with pathologies involved in neurodegenerative diseases [19]. Several studies have demonstrated that p38 MAPK is upregulated during microglial inflammation [20]. Evidence suggests that patients with neurodegenerative diseases such as AD might benefit from p38 MAPK inhibitors [21]. Therefore, there is a need to develop compounds which can interfere with the activities of these kinases, hence modulate age related as well as activated microglia-associated neuroinflammatory diseases.

Recently, it has been revealed that natural components, plant extracts, and polyunsaturated fatty acids are useful for the prevention of neurodegenerative diseases [22, 23]. Extracts containing polyphenols and vitamin E have shown to confer neuroprotection in animal models [24, 25]. One of such extracts containing these components is rice bran extract (RBE). Rice bran is obtained as a by-product in the rice milling process, a method in which the outer layer of rice grain is removed. Rice bran and its ingredients have been shown to impart a number of health-promoting functions. These functions include cholesterol-lowering, prevention of ulcer formation, anti-oxidant, anti-inflammatory, anti-diabetic, and immunomodulatory effects [2629]. The main components of rice bran are tocotrienols, tocopherols, and oryzanols (a mixture of ferulic acid esters of triterpene alcohol and phytosterols) [30]. In comparison with pure rice bran (which gets quickly rancid, leaving bran inedible), the above mentioned components are enriched with stabilized Egyptian rice bran extract. The recent studies are showing the beneficial effects of stabilized Egyptian RBE in aging- and dementia-associated disease models. For instance, Hagl et al. reported that the oral consumption of RBE for 3 weeks improved aging-related mitochondrial dysfunction in 18-month-old Naval Medical Research Institute mice (NMRI) [31]. In an another attempt, authors showed that RBE compensates mitochondrial dysfunction in an in vitro model of early AD [32]. More recently, RBE-supplemented diet showed its potential in decreasing inflammation associated to metabolic disorders [33]. To date, it is not established whether RBE interferes in microglial activation, a critical event in inflammation-associated neurodegenerative diseases. Consequently, we have investigated the effects of RBE in LPS-activated primary rat microglia.


All experiments and animal procedures were performed according to the guidelines of ethics committee of University of Freiburg Medical School under approved protocol (Nr. X-13/06A). Animals were obtained from Center for Experimental Models and Transgenic Services-Freiburg (CEMT-FR). Maximum efforts were made to minimize the number of animals used and their suffering during this study.


Heat-stabilized Egyptian rice bran extract was kindly provided by Dr. Amr Helal from IT&M S.A. (Giza, Egypt). After overnight maceration in ethanol, three successive extraction sessions under reflux at 40 °C were applied. The extraction ratio was 3:1. The extract was evaporated under vacuum at a temperature not exceeding 50 °C. The vitamin E profile of the RBE was quantified by HPLC, described elsewhere [30, 34] and as follows (all values in μg/g): alpha-tocopherol, 86; beta-tocopherol, 71; gamma-tocopherol, 288; delta-tocopherol, 93; alpha-tocotrienol, 55; beta-tocotrienol, not detectable; gamma-tocotrienol, 2226; and delta-tocotrienol, 266. LPS from Salmonella typhimurium (Sigma Aldrich, Deissenhofen, Germany) was resuspended in sterile phosphate-buffered saline (PBS, 5 mg/ml) as stock, subsequently used at a final concentration (10 ng/ml) in the cultures. The (±)-α-tocopherol (Sigma Aldrich, Deissenhofen, Germany) was dissolved in ethanol as 100 mM stock solution. Recombinant macrophage-colony stimulating factor (M-CSF) was used at 50 ng/ml as final concentration (Thermo Fisher Scientific, Darmstadt, Germany).

Primary microglia cultures

Primary mixed glial cell cultures were established from cerebral cortices of 1-day neonatal Sprague–Dawley rats as described in our previous studies [35]. In brief, brains were carefully taken. Cerebral cortices were collected and freed from meninges. Forebrains were then minced and gently dissociated by repeated pipetting in Dulbecco’s modified Eagle’s medium (DMEM) and filtered by passing through 70-μm nylon cell strainer (BD biosciences, Heidelberg, Germany). Cells were collected by centrifugation (1000g, 10 min) and resuspended in DMEM containing 10 % fetal calf serum (FCS) (GE Healthcare, Germany) and antibiotics 1 % penicillin and streptomycin (40 U/ml and 40 μg/ml, respectively) (Sigma Aldrich, Germany). Cells were then cultured on 10-cm cell culture dishes (Falcon, Heidelberg, Germany) with the density of 5 × 105 cells/ml in 5 % CO2 at 37 °C. After 12–14 days in vitro, floating microglia were harvested from mixed glia (astrocyte-microglia) cultures and re-seeded into cell culture plates at the density of either 2 × 105 cells/well or 1.2 × 106 cells/dish. On the next day, medium was removed to get rid of non-adherent cells and fresh medium was added. After 1 h, the cells were stimulated for respective experiments.

Cell viability assay

Viability of primary rat microglia after treatment with RBE was measured by the CellTiter-Glo® Luminescent Cell Viability Assay (Promega). This assay is used to determine the number of metabolically active and viable cells, based on the quantitation of ATP present in the cells. Cells (2 × 105/ml) were cultured for 24 h, subsequently incubated with RBE (10–300 μg/ml) for 24 h. Thereafter, the cells were treated with or without LPS (10 ng/ml) for the next 24 h. RBE was dissolved in ethanol and ethanol was used in the control wells (at final conc. of 0.15 %) during experiments. After 48 h of incubation, the concentration of ATP was measured after adding 100 μl of reconstituted substrate (for 10 min). Thereafter, luminescence was measured in GloMax® Luminometer (Promega).

Determination of PGE2 and 8-iso-PGF production from LPS-activated microglia

Cultured primary rat microglia were incubated with either RBE (10–300 μg/ml) or with α-tocopherol (10–100 μM) for 24 h. Afterwards, the cells were treated with or without LPS (10 ng/mL) for the next 24 h. After the end of the incubation period, supernatants were collected and centrifuged at 1000g for 5 min at 4 °C. PGE2 and 8-iso-prostaglandin F (8-iso-PGF) production was assessed in cell supernatants with a commercially available enzyme immunoassay (EIA) kit (Biotrend, Cologne, Germany, and Cayman Chemicals, Ann Arbor, Michigan, USA) respectively, followed by measurement at 450 nm according to manufacturer’s instructions. For PGE2, standards from 39 to 2500 pg/ml were used and sensitivity of the assay was 36.2 pg/ml. The 8-iso-PGF assay has a range of standards from 0.5 to 500 pg/ml and sensitivity approximately of 3 pg/ml.

Determination of TNF-α, IL-1, and IL-6 release in microglia

Effects of RBE and α-tocopherol were also studied by determining the release of various cytokines. Briefly, microglia were pre-incubated either with RBE (50–300 μg/ml) or with α-tocopherol (10–100 μM). Afterwards, LPS (10 ng/ml) was added for 24 h, and release of tumor necrosis factor (TNF)-α and IL-6 was determined in the cell supernatants which were collected after centrifugation at 1000g for 5 min at 4 °C. For the release of IL-1β at the end of the incubation, ATP (1 mM) was added for 30 min in all the wells followed by the collection of cell supernatants. Addition of ATP was important since maturation and release of IL-1β is dependent on the IL-1β converting enzyme (ICE)/caspase 1. For determination of TNF-α (eBioscience, Frankfurt, Germany), IL-6 (Thermo Fisher Scientific, Darmstadt, Germany) and IL-1β (R&D Systems Europe, Ltd., Abingdon, UK), commercially available ELISA kits were used. All the measurements were done at 450 nm according to the manufacturer’s instructions. For TNF-α, standards from 16 to 2000 pg/ml were used with sensitivity 16 pg/ml. IL-6 has a range between 23.5 and 1500 pg⁄ml with sensitivity <5 pg/ml, and IL-1β standards were between 31.5 and 2000 pg/ml with sensitivity of <5 pg/ml.


Rat primary microglia were left treated with RBE (50–300 μg/ml) for 24 h; then, the LPS (10 ng/mL) was added for different time points (depending on the studied protein). After the experiment, the cells were washed with cold PBS and lysed in the lysis buffer (42 mM Tris–HCl, 1.3 % sodium dodecyl sulfate, 6.5 % glycerin, 100 μM sodium orthovanadate, and 2 % phosphatase and protease inhibitors). Protein concentration of the samples was measured using the bicinchoninic acid (BCA) protein assay kit (Thermo Fisher Scientific, Bonn, Germany) according to the manufacturer’s instructions. For western blotting, 10–20 μg of total protein from each sample was subjected to sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) under reducing conditions. Afterward, proteins were transferred onto polyvinylidene fluoride (PVDF) membranes (Millipore, Germany). After blocking with 5 % milk solution (BioRad, Munich, Germany) in Tris-buffered saline (TBS) containing 0.1 % Tween 20 (TBS-T), membranes were incubated with primary antibodies. Primary antibodies used were goat anti-COX-2 (1:500; Santa Cruz Biotechnology, Heidelberg, Germany), rabbit anti-mPGES-1 (1:6000; Agrisera, Vännas, Sweden), anti-inhibitor of kB (IkB)-α (1:500; Santa Cruz Biotechnology), anti-p44/42 (1:1000; Cell Signaling Technology, Frankfurt, Germany), anti-p38 (1:1000; Cell Signaling Technology), anti-JNK (1:1000; Cell Signaling Technology), anti-phospho p44/42 (1:1000; Cell Signaling Technology), anti-phospho-p38 (1:1000; Cell Signaling Technology), anti-phospho-JNK (1:1000; Cell Signaling Technology), and rabbit anti-actin (1:5000; Sigma Aldrich). Primary antibodies were diluted in TBS-T and 5 % BSA. Membranes were incubated with the primary antibody overnight at 4 °C followed by incubation in secondary antibodies. After extensive washing (three times for 10 min each in TBS containing 0.1 % Tween 20), proteins were detected with either horseradish peroxidase (HRP)-coupled anti-goat IgG (Santa Cruz Biotechnology) or anti-rabbit IgG (R&D systems, Wiesbaden-Nordenstadt, Germany) using enhanced chemiluminescence (ECL) reagents (GE Healthcare, Freiburg, Germany). Densitometric analysis was performed using ImageJ software (NIH, USA), and a β-actin control was used to confirm equal sample loading and normalization of the data.

Real-time quantitative PCR

Quantitative real-time PCR (qPCR) was performed to determine the transcriptional regulation of COX-2, mPGES-1, TNF-α, IL-1β, IL-6, and IL-10 by RBE in activated microglia. RNA preparation was done by using RNAspin mini RNA isolation kit (GE Healthcare, Freiburg, Germany) and for cDNA synthesis, 1 μg of total RNA was reverse transcribed using M-MLV reverse transcriptase and random hexamers (Biomers, Ulm, Germany). The synthesized cDNA was the template for the real-time PCR amplification that was carried out by the CFX96 real-time PCR detection system (Bio-Rad Laboratories, Inc.) using iQTM SYBRTM Green supermix (Bio-Rad Laboratories GmbH, Munich, Germany). Specific primers were designed by using Universal Probe Library Assay Design Center (Roche) and were obtained from Biomers (Ulm, Germany). Reaction conditions were 3 min at 95 °C, followed by 40 cycles of 15 s at 95 °C, 30 s at 50 °C, and 45 s at 72 °C, and every cycle was followed by plate reading. After that, 1 min at 95 °C, 1 min at 55 °C, followed by melt curve conditions of 65 °C, 95 °C with increment of 0.5C for 5 s, followed by final plate reading. Glyceraldehyde 3-phosphate dehydrogenase (GAPDH) served as an internal control for sample normalization, and the comparative cycle threshold Ct method was used for data quantification as described previously [36]. The following primer sequences were used in the present study. COX-2: Fwd 5′-GGCTTACAAGACGCCACATCACCT-3′; Rev 5′-TGGTTTAGGCGGCCGGGGAT-3′; mPGES-1: Fwd 5′-AGGCCAAGTCAGGCTGCGGA-3′; Rev 5′-GTCGTTGCGGTGGGCTCTGAG-3′; TNF-α: Fwd 5′-CCCACGTCGTAGCAAACCACCA-3′; Rev 5′-CCATTGGCCAGGAGGGCGTTG-3′; IL-1β: Fwd 5′-TGTGATGAAAGACGGCACAC-3′; Rev 5′-CTTCTTCTTTGGGTATTGTTTGG-3′; IL-6: Fwd 5′-CCTGGAGTTTGTGAAGAACAACT-3′; Rev 5′-GGAAGTTGGGGTAGGAAGGA-3′; IL-10: Fwd 5′-AGTGGAGCAGGTGAAGAATGA-3′; Rev 5′-TCATGGCCTTGTAGACACCTT-3′; GAPDH: Fwd 5′-TGGGAAGCTGGTCATCAAC-3′; Rev 5′-GCATCACCCCATTTGATGTT-3′.

Flow cytometry

Microglial cells were pre-incubated with RBE (50–300 μg/ml) for 24 h; thereafter, LPS (10 ng/ml) was added for the next 24 h. Flow cytometry-based cell cycle analysis was performed as previously described with few modifications [37]. After the end of the incubation period, the media was removed and cells were washed with warm PBS. Subsequently, cells were detached from the culture dishes using 0.05 % trypsin (incubated at 37 °C, 5 min) and were then suspended in medium containing 10 % FCS. Afterwards, the cells were centrifuged (1000 rpm, 5 min) and the pellet was suspended in PBS and fixed overnight with 70 % ethanol. The next day, permeabilization (0.05 % Triton X-100) and staining with propidium iodide (PI, 50 μg/ml; 0.1 mg/ml RNaseA in PBS) was performed by incubating the cells for 40 min at 37 °C. Thereafter, stained cells were centrifuged (at 1500 rpm for 5 min) and pellet was suspended in 500 μl of PBS for flow analysis. The DNA content was then quantified using a FACScaliburTM flow cytometer (BD Biosciences, San Jose, CA, USA) equipped with argon laser (488 nm). While running the cytometer, dot plots were displayed to identify the cells based on their physical parameters on the forward scatter light (FSC) vs. side scatter light (SSC). To evaluate cell cycle progression, samples were acquired with the FL-2 fluorescence channel set to a linear scale, which allows better characterization of the G0/G1 and G2/M DNA peaks. Pulse processing was used to exclude cell doublets and clumps from the analysis. This can be achieved by using pulse area vs. pulse width. For the analysis, a gate was set on the single cell population using pulse width vs. pulse area. Then, this gate was applied to the scatter plot to gate out obvious debris. Thereafter, gates were combined and applied to the PI histogram plot. To quantitate the percentage of cells in each cell cycle phase, markers were set within the analysis program.

Statistical analysis

Statistical analyses were performed using Prism 5 software (GraphPad software Inc., San Diego, CA, USA). Values of all experiments were represented as mean ± SEM of at least three independent experiments. Raw values were converted to percentage and LPS (10 ng/ml) was considered as 100 %. Values were compared using one-way ANOVA with post hoc Student-Newman-Keuls test (multiple comparisons). The level of significance was set at *p < 0.05, **p < 0.01, and ***p < 0.001.


RBE significantly reduced the LPS-induced PGE2 release without any detrimental effects on the viability of cells

To investigate whether RBE exerts anti-inflammatory effects, microglia cells were pre-incubated with RBE (10–300 μg/ml) for 24 h and then stimulated with or without LPS (10 ng/ml) for the next 24 h. As a result, we observed a marked increase in the production of PGE2 in the supernatants of microglia cells stimulated with LPS (6831 ± 799.0 pg/ml, p < 0.001) as compared to unstimulated cells (78.27 ± 24.27 pg/ml). Treatment with RBE for 24 h prior to stimulation with LPS resulted in a significant decrease in the release of PGE2 when compared with LPS (considered as 100 %). Significantly reduced levels of PGE2 were evident starting from the concentration of 25 μg/ml RBE (61.97 ± 1.70 %, p < 0.05), and a maximal decrease was observed at the concentration of 300 μg/ml (15.57 ± 5.90, p < 0.001) as shown in Fig. 1a. To rule out whether these effects were due to the decrease in the cell viability, ATP cell viability assay was performed. Obtained data showed that all the concentrations (ranging from 10 to 300 μg/ml) had no adverse effects on ATP levels and thus viability of the microglial cells. Control cells incubated with ethanol (used as solvent for RBE) at the end concentration of 0.15 % had no adverse effects on the viability. This conveys that reduction in the levels of PGE2 by RBE was not due to the cytotoxicity. More interestingly, the concentrations ranging from 50 to 300 μg/ml further elevated the levels of ATP in activated microglia as depicted in Fig. 1b. In addition, RBE (300 μg/ml) itself significantly increased the ATP levels under basal conditions (non-activated). Given the pro-proliferative function of vitamin E congeners [38], we suspected that increased levels of ATP by RBE might be due to its interference in the microglial cell cycle, increasing DNA content, hence affecting the viability of cells. Therefore, we performed cell cycle analysis by using DNA dye-propidium iodide (see Additional file 1: Figure S1(A-K)). As a result, we observed a tendency towards the enhancement of S and G2/M phases after 48-h incubation of RBE (300 μg/ml) in comparison with the control cells but, it did not reach to a statistical significant value (Additional file 1: Figure S1(K)). Since there was a further enhancement of ATP levels with RBE (threshold concentration of 50 μg/ml) in LPS-activated microglia (see Fig. 1b), we also performed assays with RBE (50–300 μg/ml) in activated microglia. Consequently, a trend (between RBE 100–300 μg/ml) towards an increase in percentage of cells in S and G2/M phases has seen as compare with LPS (10 ng/ml), indicating a minor enhancement of cell proliferation.
Fig. 1
Fig. 1

a Rice bran extract (RBE) inhibits the release of prostaglandin E2 (PGE2) in lipopolysaccharide (LPS)-activated microglia. b RBE did not exert any adverse effects on viability in LPS-stimulated microglia cells. Microglia were pre-treated with RBE (10–300 μg/ml) for 24 h; afterwards, cells were activated with or without LPS (10 ng/ml) for the next 24 h. At the end of incubation, cell supernatants were collected and release of PGE2 (a) was measured by enzyme immune assay (EIA). ATP assay was performed to assess the microglia cell viability after RBE (10–300 μg/ml) treatment in the absence or presence of LPS (10 ng/ml). For a detailed measurement protocol, see the “Methods” section. Statistical analyses were carried out by using one-way ANOVA with post hoc Student-Newman-Keuls test (multiple comparisons). Results are expressed as means ± SEM of at three independent experiments. * p < 0.05; ** p < 0.01; *** p < 0.001 compared with LPS (10 ng/ml)-activated cells; # p < 0.001 compared with control cells

RBE inhibits the free radical formation in LPS-induced rat microglia

Given the anti-oxidant properties of RBE [39], we also speculated that RBE might exert its anti-oxidative effects in activated microglia. To this end, we studied the effects of RBE on the formation of free radical formation in LPS-activated microglia. Measurement of 8-iso-PGF release is taken as a sensitive marker to assess free radical formation [40], and we have previously shown that LPS significantly increases the levels of 8-iso-PGF in primary microglia [41]. Indeed, here, we also observed that LPS (10 ng/ml) significantly enhanced the levels of 8-iso-PGF (134.8 ± 12.08 pg/ml, p < 0.001) as compared to basal levels (44.15 ± 15.80 pg/ml). Pre-incubation of RBE for 24 h reduced the levels of released 8-iso-PGF in LPS-activated microglia. This reduction in the levels was achieved ranging from the concentration of RBE 100 μg/ml (53.73 ± 6.57 %, p < 0.05), RBE 200 μg/ml (44.97 ± 6.76 %, p < 0.05), and 300 μg/ml (49.16 ± 8.54 %, p < 0.05). RBE did not show any effect in the formation of isoprostane under control conditions (Fig. 2).
Fig. 2
Fig. 2

RBE inhibits the release of 8-isoprostane (8-iso-PGF) in LPS-activated microglia. Microglia cells were pre-treated with RBE (10–300 μg/ml) for 24 h; thereafter, cells were incubated with or without LPS (10 ng/ml) for the next 24 h. At the end of incubation, cell supernatants were collected and release of 8-iso-PGF was measured by EIA. Statistical analysis was carried out by using one-way ANOVA with post hoc Student-Newman-Keuls test (multiple comparisons). Results are expressed as means ± SEM of three independent experiments. * p < 0.05 compared with LPS (10 ng/ml)-activated cells

RBE supresses the PGE2 production by inhibiting the COX-2 and mPGES-1 expressions in LPS-activated microglia

PGE2 is synthesized during microglia activation through the enzymatic action of COX-2 and mPGES-1. It is known that mPGES-1 is coupled with COX-2 in the biosynthesis of PGE2. Consequently, we determined whether the effect of RBE on PGE2 was mediated through an inhibition of the synthesis of these enzymes. As shown in Fig. 3a, RBE (50 μg/ml) did not cause a significant reduction in COX-2 protein expression in activated (LPS 10 ng/ml) microglia. However, significant reduction in COX-2 immunoreactivity was observed initially at 100 μg/ml and was strongly inhibited at 200 and 300 μg/ml. On the contrary, inhibition of mPGES-1 protein levels started already with the lowest concentration of 50 μg/ml, stronger effects were seen at 100 μg/ml, and maximal effects were achieved at 200 μg/ml as compared to 300 μg/ml as shown in Fig. 3b. However, RBE did not significantly alter the expression of COX-2 (only a marginal increase observed) and mPGES-1 under non-activated state of microglia (Additional file 2: Figure S2 and Additional file 3: Figure S3 (B)). These data suggest that reduction in the release of PGE2 by RBE is due to decreased expression of COX-2 and mPGES-1.
Fig. 3
Fig. 3

Effects of RBE on protein levels of COX-2 and mPGES-1 in LPS-activated microglia. Cells were pre-treated with RBE (50–300 μg/ml) for 24 h followed by incubation of cells with or without LPS (10 ng/ml) for the next 24 h. Whole cell lysates were subjected to western blot for COX-2 and mPGES-1. Representative blots for COX-2 and mPGES-1 are shown (a, b, upper panel) and densitometric analyses were performed (a, b, lower panel). To confirm equal sample loading, membranes were stripped and reprobed for β-actin and the data were used for normalization. Statistical analyses were carried out by using one-way ANOVA with post hoc Student-Newman-Keuls test (multiple comparisons). Results are expressed as means ± SEM of three to five independent experiments. * p < 0.05; ** p < 0.01; *** p < 0.001 compared with LPS (10 ng/ml)-activated cells

Inhibition of p38 MAPK, ERK1/2, and JNK activation contributes to the anti-inflammatory effects of RBE

The role of MAPKs in neuroinflammation and Alzheimer’s disease is well evident [21, 42, 43]. The major MAPK pathway subfamilies involved in the regulation of COX-2/mPGES-1 and cytokine synthesis in LPS-activated microglia are signaling proteins such as extracellular signal-regulated kinases (ERK1/2) or (p44/42 MAPK), JNK, and p38 MAPK. Therefore, we studied the possible effects of RBE on the phosphorylation of these kinases in primary rat microglia. As a result, pre-incubation of RBE for 24 h has differential effects on the phosphorylation of p38, ERK1/2, and JNK in LPS (10 ng/ml)-activated microglia. Interestingly, reduction in the phosphorylation of p38 with RBE was achieved as low as with 50 μg/ml (~35 %, p < 0.05), which was further reduced (~60 %, p < 0.01) with higher concentrations (RBE 100 and 200 μg/ml). The phosphorylated levels remained significantly low with the highest concentration of RBE (300 μg/ml), (~40 %, p < 0.05) as shown in Fig. 4a
Fig. 4
Fig. 4

Effects of RBE on the activation of p38 MAPK and ERK 1/2 MAPK. Cells were pre-treated with RBE (50–300 μg/ml) for 24 h followed by stimulation with or without LPS (10 ng/ml) for 30 min. Whole cell lysates were subjected to western blots analyses. Representative blots (upper panel) and densitometry analyses (lower panel) are shown a p38 MAPK and b ERK 1/2. Statistical analyses were carried out by using one-way ANOVA with post hoc Student-Newman-Keuls test (multiple comparisons). Results are expressed as means ± SEM of three to four independent experiments. * p < 0.05; ** p < 0.01; *** p < 0.001 compared with LPS (10 ng/ml)-activated cells

As shown in Fig. 4a, significant reduction of pERK (~50 %, p < 0.05) was only achieved with the highest concentration of RBE (300 μg/ml). However, only a tendency towards decrease was observed with lower concentrations but did not reach a significant statistical value (Fig. 4b). Furthermore, RBE (200 μg/ml) exerted inhibition of ~40 % (p < 0.05) and RBE (300 μg/ml) ~60 % (p < 0.001) of the activation of JNK in microglia (Fig. 5a). Furthermore, we also studied if RBE itself has any significant influence on the phosphorylation of the abovementioned kinases. Similarly, RBE did not alter the phosphorylation of p38MAPK, ERK (only marginal increase but not significant), and JNK under non-activated state of microglia (Additional file 4: Figure S4 (A-C)).
Fig. 5
Fig. 5

Effects of RBE on the activation of JNK and degradation of IkB-α induced by LPS. Cells were pre-treated with RBE (50–300 μg/ml) for 24 h followed by stimulation with or without LPS (10 ng/ml) for 30 min (for phospho-JNK) and 15 min (for IkB-α). Whole cell lysates were subjected to western blots analyses. Representative blots (upper panel) and densitometry analyses (lower panel) are shown a pJNK and b IkB-α. Statistical analyses were carried out by using one-way ANOVA with post hoc Student-Newman-Keuls test (multiple comparisons). Results are expressed as means ± SE of three three to four independent experiments. * p < 0.05; ** p < 0.01; *** p < 0.001 compared with LPS (10 ng/ml)-activated cells or control cells (for IkB-α graph)

Anti-inflammatory effects of RBE were independent of IkB-α degradation

One of the first responses of the microglia to LPS stimulation is the phosphorylation and degradation of IkB. In resting cells, NF-kB is sequestered in the cytoplasm by the inhibitory IkB protein. When activated by a stimulus, such as LPS, IkB is phosphorylated by IKK. Phosphorylated IkB then undergoes ubiquitination and degradation [44] and allows the NF-kB to translocate to the nucleus and thereby facilitates the transcription of various pro-inflammatory genes. The decay of IkB-α is used as an indicator of NF-kB activation [35, 45]. Therefore, we also studied the effects of RBE on the degradation of IkB-α. Stimulation of LPS (10 ng/ml) for 15 min led to the degradation of IkB-α while pre-incubation of RBE for 24 h failed to reverse this effect (Fig. 5b), suggesting that the regulatory effects of RBE on microglia activation are confined to the MAPK pathway.

Effects of RBE on the LPS-mediated synthesis of pro-inflammatory and anti-inflammatory cytokines

We furthermore tested whether the effects of RBE were confined to the reduction of PGE2 and isoprostane release or if they also affect other inflammatory molecules. To this end, we studied the effects of RBE on the gene expression as well as release of pro-inflammatory cytokines (TNF-α, IL-1β, and IL-6). These cytokines are known to be important mediators of microglia inflammation [35]. Stimulation of microglia cells with LPS (10 ng/ml) for 4 h led to a significant increase in normalized expression of TNF-α (LPS, 1.75 ± 0.21 vs. control, 0.005 ± 0.0005, p < 0.001), IL-1β (LPS, 1.31 ± 0.067 vs. control, 0.003 ± 0.0007, p < 0.001), and IL-6 (LPS 0.91 ± 0.09 vs. control 0.0 ± 0.0, p < 0.001) as shown in Fig. 6ac. Pre-treatment of RBE for 24 h significantly reduced the expression of TNF-α and IL-1β but failed to impart any effect on the expression of IL-6 (Fig. 6c). Mild reduction in the expression of TNF-α started at 100 μg/ml of RBE (77.07 ± 4.96 %, p < 0.05), moderate at 200 μg/ml (62.27 ± 6.59 %, p < 0.01) and achieved maximal effects at 300 μg/ml (46.31 ± 3.96 %, p < 0.001) as depicted in Fig. 6a. Pre-treatment of RBE (50 and 100 μg/ml) did not show any significant modulatory effects on the expression of IL-1β (Fig. 6b). However, with the higher concentrations of RBE (200 and 300 μg/ml), a significant decrease of ~25 % (p < 0.05) was observed as compared with LPS 10 ng/ml (taken as 100 %). Furthermore, in case of release of cytokines, 24-h stimulation of microglia with LPS (10 ng/ml) leads to a significant upregulation of TNF-α (control, 7.71 ± 2.57 pg/ml vs. LPS, 1401 ± 130 pg/ml), IL-6 (control, 52.73 ± 2.64 pg/ml vs. LPS, 1086 ± 88.40 pg/ml), and IL-1β (control, 1.35 ± 1.35 pg/ml vs. LPS + ATP, 316.8 ± 87.01 pg/ml). Similarly, cells with the prior treatment of RBE had less levels of TNF-α and IL-1β whereas levels of IL-6 did not alter significantly as shown in Fig. 7ac. Of note, in case of IL-1β release, addition of ATP (30 min prior to collection of supernatants from culture wells) was important since release of IL-1β is dependent on the ICE/caspase 1. ATP via the P2X7 receptor acts as extracellular trigger for ICE/caspase 1 activation. Therefore, we did not see any significant changes in the extracellular accumulation of IL-1β with LPS (10 ng/ml, for 24 h) in the absence of ATP (data not shown in the graph). All of these above data suggest specific effects of RBE (at various threshold concentrations) on distinct inflammatory mediators in microglia. In order to understand if RBE has any modulatory effects on the polarity of microglia (M1, pro-inflammatory vs. M2, anti-inflammatory), gene expression of the well-accepted M2 cytokine (IL-10) was studied using real-time PCR. In contrast to pro-inflammatory cytokines, treatment of RBE led to further augmentation of IL-10 gene expression starting from RBE 50 μg/ml (176.7 ± 17.07 %, p < 0.01), at RBE 100 μg/ml (170.3 ± 16.36 %, p < 0.01), at RBE 200 μg/ml (183.9 ± 18.79 %, p < 0.01), and reached a maximum at RBE 300 μg/ml (229.5 ± 23.22 %, p < 0.001) as shown in Fig. 6d. These data indicate that RBE might be involved in polarizing microglia by influencing the expression of pro- and anti-inflammatory cytokines. Additionally, to seek the experimental evidences if these beneficial effects of RBE in microglia can be mimicked by α-tocopherol (one of the active components of RBE), various assays have been performed. Briefly, experiments were performed with α-tocopherol (10–100 μM) in a similar manner as of RBE to see if α-tocopherol can mimic all or some of the data we got with RBE treatment. Interestingly, we did not observe any significant changes in the levels of PGE2, TNF-α, IL-1β, and IL-6 (see Additional file 5: Figure S5 (A-D)). These data indicates that effects mediated by RBE in microglia cannot be explained by the α-tocopherol alone.
Fig. 6
Fig. 6

Effects of RBE on the gene expression of TNF-α, IL-1β, IL-6, and IL-10 in LPS-activated microglia. Cells were pre-treated with RBE (50–300 μg/ml) for 24 h followed by stimulation with or without LPS (10 ng/ml) for 4 h. Afterwards, gene expression of a TNF-α, b IL-1β, c IL-6, and d IL-10 was analyzed by real-time quantitative PCR. GAPDH was used as an internal control for normalization and data were quantified by using comparative cycle threshold Ct method. Data are presented as percentage control of LPS. Results are expressed as means ± SEM of three to five independent experiments. Statistical analyses were carried out by using one-way ANOVA with post hoc Student-Newman-Keuls test (multiple comparisons). * p < 0.05; ** p < 0.01; *** p < 0.001 compared with LPS (10 ng/ml)-activated cells

Fig. 7
Fig. 7

Effects of RBE on the release of TNF-α, IL-1β, and IL-6 in LPS-activated microglia. Cells were pre-treated with RBE (50–300 μg/ml) followed by stimulation with or without LPS (10 ng/ml) for 24 h. Afterwards, release of a TNF-α, b IL-1β, and c IL-6 was analyzed by ELISA. Data are presented as percentage control of LPS. Results are expressed as means ± SEM of three to four independent experiments. Statistical analyses were carried out by using one-way ANOVA with post hoc Student-Newman-Keuls test (multiple comparisons). * p < 0.05; ** p < 0.01; *** p < 0.001 compared with LPS (10 ng/ml)-activated cells

Fig. 8
Fig. 8

Schematic showing the effects of RBE on LPS-activated microglia. Stimulation of Toll-like receptor (TLR)-4 by LPS resulted in a phosphorylation and thus activation of mitogen-activated protein kinases (MAPK) signal cascade as well as NF-kB pathway. RBE exerted its beneficial effects by interfering in the activation of key kinases in MAPK signaling cascade but failed to affect NF-kB pathway. These effects of RBE were corroborated by reduction in the levels of COX-2/mPGES-1 and hence PGE2 production. RBE also imparted its anti-inflammatory effects by reducing the expression of pro-inflammatory cytokines (M1 markers; IL-1β and TNF-α) and by counterbalancing the levels of anti-inflammatory cytokine (M2 marker; IL-10) in microglia. Moreover, these beneficial effects of RBE are possibly due to, at least in part, by reduction in free radical formation (8-isoprostane) in microglia


In this study, we demonstrate that RBE inhibits microglia activation by suppressing the production of PGE2 and 8-iso-PGF—a marker for free radical production. RBE exhibited further beneficial effects by reducing pro-inflammatory cytokines (TNF-α and IL-1β). In addition, pre-stimulation with RBE for 24 h enhanced the expression levels of anti-inflammatory (IL-10) cytokine in LPS-stimulated rat microglia. Furthermore, we were also able to dissect the underlying signaling mechanism/s by which RBE imparted its beneficial effects, schematically represented in Fig. 8. To the best of our knowledge, this is the very first evidence for the anti-inflammatory effects of RBE in the immune cells of CNS. Immunomodulatory effects of rice bran (black and brown) extract in the peripheral nervous system (PNS) of CD-1 mice have previously been explored [46]. This study showed the anti-inflammatory activities of black rice bran (10 mg/kg body weight) in a topical application of TPA (12-O-tetradecanolylphorbol-13-acetate)-induced skin edema. Anti-inflammatory actions exerted by black rice bran in this study were due to the suppression of TNF-α, IL-6, and IL-1β leaving PGE2 production unchanged, whereas brown rice bran extract had no effect on studied molecules. This study is in contrast to ours, at least in part, where we showed significant downregulation of PGE2 without affecting the IL-6 production. This inconsistency in studies might be explained due to the different study models (CNS vs. PNS; in vitro vs. in vivo). Another explanation might lie in the different composition and stability of RBE due to the distinct extraction methods. We observed that RBE did not reduce the survival of microglial cells either alone or in combination with LPS. More interestingly, RBE further elevated the levels of ATP under basal as well as in stimulated conditions. These findings are in agreement with the previous findings where the authors showed the beneficial effects of RBE on mitochondrial dysfunction. These activities of RBE were attributed to restoring mitochondrial endogenous respiration and ATP contents [31, 32]. One can speculate that restoration of mitochondrial function by RBE was owing to its anti-inflammatory and anti-oxidant features. There are few evidences showing that mitochondrial function may require a multifaceted approach that includes drugs and plant-derived phenolic compounds with anti-oxidant and anti-inflammatory activities [47]. It is not precisely clear if such correlation exists in our model, and we believe that this is intriguing and worth exploring in our future studies. Another reason for the increase in ATP levels might be due to an enhancement in the proliferation of microglia after RBE treatment. To find this out, we performed cell cycle analysis. As a result, we did observe a tendency towards an enhancement of microglial proliferation with RBE but it did not reach to a significant statistical value. Thus, we believe that this enhancement in proliferation might have contributed towards enhanced levels of ATP as shown in viability assay but we cannot rule out other factors, which warrant further assessment. Moreover, to the best of our knowledge, there is no such study investigating the proliferation after RBE treatment in the brain (in vivo) or in glial cell cultures. Though in contrast, there are previous studies showing the anti-proliferative actions of rice bran or RBE in cancerous cell lines. For example, water-soluble enzymatic extract from rice bran (EERB) imparted its anti-proliferative effects in human T cell acute lymphoblastic leukemia (MOLT-4) [48]. Another study by a Japanese group showed the immunomodulatory and anti-proliferative effects of various rice bran extracts (red, black, brown) in culture immunocompetent cells [49]. All of these studies have various experimental differences in comparison with our study. These studies were done with much higher concentrations of RBE (e.g., 300 μg/ml vs. 10 mg/ml); another differences were primary cell cultures vs. cell lines and differences in the variety of rice bran and preparation of extract. If we look at the effects of vitamin E congeners (tocopherols and tocotrienols) on the proliferation, there are ample evidences proving the pro-proliferative effects. For example, Ren et al. showed that tocotrienols induce lymphocyte proliferation, and the study by Flanary and Streit showed that α-tocopherol induces proliferation in cultured rat microglia [38, 50]. Thus, in our study, this enhancement of proliferation of microglia might have come through tocopherol or tocotrienols or via synergistic effects of both.

Next, we examined the effects of RBE on the formation of 8-iso-PGF—an index of oxidative stress-mediated production of lipid hydroperoxides. In postmortem brains of AD patients, levels of F2-isoprostane have been shown to be elevated [51, 52]. Earlier, we have demonstrated the ability of natural products to inhibit the 8-iso-PGF in activated microglia [41, 53]. Similarly, our current findings with RBE show that the extract affects the formation of free radicals in microglia, confirming the anti-oxidant properties of this extract.

The COX-2/mPGES-1 enzyme pathway and subsequent generation of prostaglandins play a significant role in microglia activation. mPGES-1 is the terminal enzyme for the biosynthesis of PGE2 during inflammation and is normally functionally coupled with COX-2 with few exceptions [18]. This enzyme is markedly induced by pro-inflammatory stimuli and is downregulated by anti-inflammatory glucocorticoids. In order to gain a better understanding of the mechanism of action of RBE, we investigated its effect on COX-2 and mPGES-1 protein levels in LPS-treated microglia. Our data show that RBE inhibited COX-2 and mPGES-1 after 24 h of LPS stimulation, suggesting that RBE acts to reduce PGE2 production by interfering with both COX-2 and mPGES-1 protein synthesis in LPS-activated microglia. Previously, the stabilized RBE has shown to inhibit the activity of COX-2 enzyme in a cell-free system [54]. In this study, an effect of RBE on the mPGES-1 was not studied, suggesting the novelty of our work.

MAPK are involved in the regulation of inflammatory events. For instance, activation of ERK and p38 MAPK are implicated in the regulation of COX-2 expression in activated microglia [15, 55]. Moreover, our group has previously shown the involvement of ERK and p38 MAPK in the induction of mPGES-1 in rat microglia [18]. In this study, a common involvement of JNK has also been reported in the regulation of both COX-2 and mPGES-1 expression. In our present study, RBE exerted strong suppressive effects on the phosphorylation of p38 and JNK following LPS induction. However, in case of pERK, only modest inhibitory effects were seen with the highest concentration of RBE (300 μg/ml). Differential regulation of these proteins at various threshold concentrations of RBE indicates specificity of its ingredients for certain proteins. For instance, at the same time, one of the ingredients has inhibitory effects on certain protein while enhancing effect on others.

NF-kB activation has been linked to neurotoxicity through production of pro-inflammatory molecules in glial cells, suggesting its role in neurodegenerative conditions [56]. We therefore determined if RBE exhibited its anti-inflammatory effects via the suppression of NF-kB activation. The inflammatory responses to NF-kB are negatively regulated by its inhibitory subunit IkB-α [57]. In the current study, we found that LPS treatment reduced IkB-α levels in microglia as compared to untreated cells while pre-incubation of RBE for 24 h did not affect IkB-α degradation. However, the fact that RBE did not affect LPS-induced IkB-α degradation suggests that reduced expression of COX-2 and mPGES-1 by RBE is independent of NF-kB activation. Most recently, the bioavailability of RBE components in the brains of Guinea pigs and aged NMRI mice were examined [31, 58]. Apart from this there are—to the best of our knowledge—no more publications about bioavailability of RBE ingredients after administration of RBE. Briefly, they found that α-tocopherol was the most abundant vitamin E derivative found in Guinea pig brains, followed by α-tocotrienol and γ-tocotrienol. Another study was performed in NMRI—one of the well-established models of senescence. Similarly, only α-tocopherol could be detected in brain homogenates of young and aged mice and concentrations of all other tocopherol and tocotrienol derivatives were below the limit of detection. Therefore, to seek the experimental evidences if these effects imparted by RBE can be mimicked by α-tocopherol, we performed various assays with α-tocopherol. Interestingly, we did not observe any significant changes in the levels of PGE2, TNF-α, IL-1, and IL-6 (see Additional file 5: Figure S5 (A-D)). These data indicates that effects mediated by RBE in microglia cannot be explained by the α-tocopherol alone. RBE is a complex blend of known as well as still unknown compounds. Thus, we think that components other than α-tocopherols might have exerted their effects in regulating microglial activation. Previously, it was shown that only vitamin E from natural sources like RBE (mixture of eight vitamin E congeners) was able to protect brain against neurodegeneration [23, 59]. Accordingly, we can hypothesize that α-tocopherol is not the only active component present in RBE; others, most importantly tocotrienols, may have also contributed towards the downregulation of microglial activation. Also, one cannot rule out the effects of polyunsaturated fatty acids (PUFA) such as alpha-linolenic acid, which is also present in RBE. Studies on diets and drugs targeting PUFA have been emerging as disease-modifying agents [60]. We believe that our present study provides the fundamental knowledge (for us and others) of effects of RBE in regulating microglial function. Thus, a more elaborated characterization of RBE contents and its accumulation in the brain is required to identify the function of particular active compound.


Altogether, our data provided the evidence that in activated microglia, RBE exerts beneficial effects by targeting COX-2/mPGES-1 in PGE2 production as well as by modulating cytokine levels. These beneficial effects are possibly due to, at least in part, anti-oxidant features of the extract. The underlying mechanism of action by which RBE exerted its anti-inflammatory effects was mainly dependent on MAPKs pathway without affecting NF-kB signaling. Thus, RBE represents the potential to regulate microglia activation (in vitro) and must be further investigated in animal models of neuroinflammation.


8-iso-PGF, 8-iso-prostaglandin F; COX-2, cyclooxygenase-2; ERK 1/2, extracellular signal-regulated kinase; IkB, inhibitor of kB; IL, interleukin; JNK, c-Jun N-terminal kinase; LPS, lipopolysaccharide; MAPK, mitogen-activated protein kinase; mPGES-1, microsomal prostaglandin E synthase-1; PGE2, prostaglandin E2; RBE, rice bran extract; TNF, tumor necrosis factor



We thank Brigitte Günter and Ulrike Götzinger-Berger for their excellent technical assistance. Harsharan Singh Bhatia and Bernd Fiebich acknowledge Alzheimer Forschung Initiative e.V. (AFI) for providing pilot grant (13852) and standard grant (10812), respectively. This study was also supported by the Federal Ministry of Economics (BMWi) in frame of the ZIM initiative project called PorridgePlus (KF3204601). Authors thank Dr. Amr Helal from IT&MS.A. (Giza, Egypt) for supplying the stabilized rice bran extract (riciplex) and Dr. Hesham El-Askary (Faculty of Pharmacy, Cairo University) for characterizing the rice bran extract. Dr. Rupinder Kaur (Department of Nanotechnology, IMTEK at University of Freiburg, Germany) is greatly acknowledged for assisting in schematic representation and English corrections.


Not applicable.

Availability of data and materials

All data is provided in manuscript and in additional files.

Authors’ contributions

HSB, BLF, and GPE participated in the research design. The experiments were performed by HSB and JB. The data were analyzed by HSB, JB, and BLF. HSB and BLF wrote the manuscript. HSB, SH, GPE, and BLF reviewed, revised, and discussed the manuscript. All authors have read and approved the final version of the manuscript.

Competing interests

The authors declare that they have no competing interests.

Consent for publication

Not applicable.

Ethics approval and consent to participate

All experiments and animal procedures were performed according to the guidelines of ethics committee of University of Freiburg Medical School under approved protocol (Nr. X-13/06A).

Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (, which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver ( applies to the data made available in this article, unless otherwise stated.

Authors’ Affiliations

Department of Psychiatry, University of Freiburg Medical School, Hauptstr. 5, Freiburg, 79104, Germany
Department of Pharmacology, Goethe University, Biozentrum Niederursel, Max-von-Laue-Str. 9, Frankfurt, 60438, Germany
VivaCell Biotechnology GmbH, Ferdinand-Porsche-Str. 5, Denzlingen, 79211, Germany
Institute of Nutritional Sciences, University of Giessen, Wilhelmstrasse 20, Giessen, 35392, Germany


  1. Bénardais K, Gudi V, Gai L, Neßler J, Singh V, Prajeeth CK, et al. Long-term impact of neonatal inflammation on demyelination and remyelination in the central nervous system: Neonatal Insult Impacts Microglia Functions. Glia. 2014;62:1659–70.View ArticlePubMedGoogle Scholar
  2. Wang Q, Liu Y, Zhou J. Neuroinflammation in Parkinson’s disease and its potential as therapeutic target. Transl Neurodegener. 2015;4:19.View ArticlePubMedPubMed CentralGoogle Scholar
  3. Philips T, Robberecht W. Neuroinflammation in amyotrophic lateral sclerosis: role of glial activation in motor neuron disease. Lancet Neurol. 2011;10:253–63.View ArticlePubMedGoogle Scholar
  4. Heneka MT, Carson MJ, Khoury JE, Landreth GE, Brosseron F, Feinstein DL, et al. Neuroinflammation in Alzheimer’s disease. Lancet Neurol. 2015;14:388–405.View ArticlePubMedGoogle Scholar
  5. Heneka MT, Kummer MP, Latz E. Innate immune activation in neurodegenerative disease. Nat Rev Immunol. 2014;14:463–77.View ArticlePubMedGoogle Scholar
  6. Cherry JD, Olschowka JA, O’Banion M. Neuroinflammation and M2 microglia: the good, the bad, and the inflamed. J Neuroinflammation. 2014;11:98.View ArticlePubMedPubMed CentralGoogle Scholar
  7. Barichello T, Generoso JS, Goularte JA, Collodel A, Pitcher MRR, Simões RP, et al. Does infection-induced immune activation contribute to dementia? Aging Dis. 2015;6:342.View ArticlePubMedPubMed CentralGoogle Scholar
  8. Loane DJ, Kumar A. Microglia in the TBI brain: the good, the bad, and the dysregulated. Exp Neurol. 2016;275:316–27.View ArticlePubMedGoogle Scholar
  9. Lambertsen KL, Biber K, Finsen B. Inflammatory cytokines in experimental and human stroke. J Cereb Blood Flow Metab. 2012;32:1677–98.View ArticlePubMedPubMed CentralGoogle Scholar
  10. Andersen JK. Oxidative stress in neurodegeneration: cause or consequence? Nat Med 2004;10:S18–25.Google Scholar
  11. Kumar A, Bhatia HS, de Oliveira ACP, Fiebich BL. microRNA-26a modulates inflammatory response induced by toll-like receptor 4 stimulation in microglia. J Neurochem. 2015;135:1189–202.View ArticlePubMedGoogle Scholar
  12. Fiebich BL, Akter S, Akundi RS. The two-hit hypothesis for neuroinflammation: role of exogenous ATP in modulating inflammation in the brain. Front Cell Neurosci. 2014;8:260.View ArticlePubMedPubMed CentralGoogle Scholar
  13. Lima IV De A, Bastos LFS, Limborço-Filho M, Fiebich BL, De Oliveira ACP. Role of prostaglandins in neuroinflammatory and neurodegenerative diseases. Mediators Inflamm. 2012;2012:1–13.Google Scholar
  14. Thameem Dheen S, Kaur C, Ling E-A. Microglial activation and its implications in the brain diseases. Curr Med Chem. 2007;14:1189–97.View ArticlePubMedGoogle Scholar
  15. Akundi RS, Candelario-Jalil E, Hess S, Hüll M, Lieb K, Gebicke-Haerter PJ, et al. Signal transduction pathways regulating cyclooxygenase-2 in lipopolysaccharide-activated primary rat microglia. Glia. 2005;51:199–208.View ArticlePubMedGoogle Scholar
  16. Jakobsson PJ, Thorén S, Morgenstern R, Samuelsson B. Identification of human prostaglandin E synthase: a microsomal, glutathione-dependent, inducible enzyme, constituting a potential novel drug target. Proc Natl Acad Sci U S A. 1999;96:7220–5.View ArticlePubMedPubMed CentralGoogle Scholar
  17. Tanikawa N, Ohmiya Y, Ohkubo H, Hashimoto K, Kangawa K, Kojima M, et al. Identification and characterization of a novel type of membrane-associated prostaglandin E synthase. Biochem Biophys Res Commun. 2002;291:884–9.View ArticlePubMedGoogle Scholar
  18. de Oliveira ACP, Candelario-Jalil E, Bhatia HS, Lieb K, Hüll M, Fiebich BL. Regulation of prostaglandin E2 synthase expression in activated primary rat microglia: evidence for uncoupled regulation of mPGES-1 and COX-2. Glia. 2008;56:844–55.View ArticlePubMedGoogle Scholar
  19. Sun A, Liu M, Nguyen XV, Bing G. P38 MAP kinase is activated at early stages in Alzheimer’s disease brain. Exp Neurol. 2003;183:394–405.View ArticlePubMedGoogle Scholar
  20. Xie Z, Smith CJ, Van Eldik LJ. Activated glia induce neuron death via MAP kinase signaling pathways involving JNK and p38. Glia. 2004;45:170–9.View ArticlePubMedGoogle Scholar
  21. Munoz L, Ammit AJ. Targeting p38 MAPK pathway for the treatment of Alzheimer’s disease. Neuropharmacology. 2010;58:561–8.View ArticlePubMedGoogle Scholar
  22. Kim HG, Oh MS. Nutraceuticals and prevention of neurodegeneration herbal medicines for the prevention and treatment of Alzheimer’s disease. Curr Pharm Des. 2012;18:57–75.View ArticlePubMedGoogle Scholar
  23. Barnard ND, Bush AI, Ceccarelli A, Cooper J, de Jager CA, Erickson KI, et al. Dietary and lifestyle guidelines for the prevention of Alzheimer’s disease. Neurobiol Aging. 2014;35(S2):S74–8.View ArticlePubMedGoogle Scholar
  24. Magrone T, Marzulli G, Jirillo E. Immunopathogenesis of neurodegenerative diseases: current therapeutic models of neuroprotection with special reference to natural products. Curr Pharm Des. 2012;18:34–42.View ArticlePubMedGoogle Scholar
  25. Virmani A, Pinto L, Binienda Z, Ali S. Food, nutrigenomics, and neurodegeneration—neuroprotection by what you eat! Mol Neurobiol. 2013;48:353–62.View ArticlePubMedGoogle Scholar
  26. Cicero AF, Gaddi A. Rice bran oil and gamma-oryzanol in the treatment of hyperlipoproteinaemias and other conditions. Phytother Res PTR. 2001;15:277–89.View ArticlePubMedGoogle Scholar
  27. Henderson AJ, Kumar A, Barnett B, Dow SW, Ryan EP. Consumption of rice bran increases mucosal immunoglobulin A concentrations and numbers of intestinal Lactobacillus spp. J Med Food. 2012;15:469–75.View ArticlePubMedPubMed CentralGoogle Scholar
  28. Justo ML, Claro C, Zeyda M, Stulnig TM, Herrera MD, Rodríguez-Rodríguez R. Rice bran prevents high-fat diet-induced inflammation and macrophage content in adipose tissue. Eur. J. Nutr. 2015;1-9Google Scholar
  29. Ghatak SB, Panchal SJ. Investigation of the immunomodulatory potential of oryzanol isolated from crude rice bran oil in experimental animal models. Phytother Res PTR. 2012;26:1701–8.View ArticlePubMedGoogle Scholar
  30. Hagl S, Berressem D, Bruns B, Sus N, Frank J, Eckert GP. Beneficial effects of ethanolic and hexanic rice bran extract on mitochondrial function in PC12 cells and the search for bioactive components. Molecules. 2015;20:16524–39.View ArticlePubMedGoogle Scholar
  31. Hagl S, Berressem D, Grewal R, Sus N, Frank J, Eckert GP. Rice bran extract improves mitochondrial dysfunction in brains of aged NMRI mice. Nutr Neurosci. 2015;19:1–10.View ArticlePubMedGoogle Scholar
  32. Hagl S, Grewal R, Ciobanu I, Helal A, Khayyal MT, Muller WE, et al. Rice bran extract compensates mitochondrial dysfunction in a cellular model of early Alzheimer’s disease. J Alzheimers Dis JAD. 2015;43:927–38.PubMedGoogle Scholar
  33. Candiracci M, Justo ML, Castaño A, Rodriguez-Rodriguez R, Herrera MD. Rice bran enzymatic extract-supplemented diets modulate adipose tissue inflammation markers in Zucker rats. Nutrition. 2014;4:466–72.View ArticleGoogle Scholar
  34. Grebenstein N, Frank J. Rapid baseline-separation of all eight tocopherols and tocotrienols by reversed-phase liquid-chromatography with a solid-core pentafluorophenyl column and their sensitive quantification in plasma and liver. J Chromatogr A. 2012;1243:39–46.View ArticlePubMedGoogle Scholar
  35. Singh V, Bhatia HS, Kumar A, de Oliveira ACP, Fiebich BL. Histone deacetylase inhibitors valproic acid and sodium butyrate enhance prostaglandins release in lipopolysaccharide-activated primary microglia. Neuroscience. 2014;265:147–57.View ArticlePubMedGoogle Scholar
  36. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods. 2001;25:402–8.View ArticlePubMedGoogle Scholar
  37. Bianco F, Ceruti S, Colombo A, Fumagalli M, Ferrari D, Pizzirani C, et al. A role for P2X7 in microglial proliferation. J Neurochem. 2006;99:745–58.View ArticlePubMedGoogle Scholar
  38. Flanary BE, Streit WJ. Alpha-tocopherol (vitamin E) induces rapid, nonsustained proliferation in cultured rat microglia. Glia. 2006;53:669–74.View ArticlePubMedGoogle Scholar
  39. Wang Y-X, Li Y, Sun A-M, Wang F-J, Yu G-P. Hypolipidemic and antioxidative effects of aqueous enzymatic extract from rice bran in rats fed a high-fat and -cholesterol diet. Nutrients. 2014;6:3696–710.View ArticlePubMedPubMed CentralGoogle Scholar
  40. Praticò D, Barry OP, Lawson JA, Adiyaman M, Hwang SW, Khanapure SP, et al. IPF2alpha-I: an index of lipid peroxidation in humans. Proc Natl Acad Sci U S A. 1998;95:3449–54.View ArticlePubMedPubMed CentralGoogle Scholar
  41. Bhatia HS, Candelario-Jalil E, de Oliveira ACP, Olajide OA, Martínez-Sánchez G, Fiebich BL. Mangiferin inhibits cyclooxygenase-2 expression and prostaglandin E2 production in activated rat microglial cells. Arch Biochem Biophys. 2008;477:253–8.View ArticlePubMedGoogle Scholar
  42. Fiebich BL, Lieb K, Engels S, Heinrich M. Inhibition of LPS-induced p42/44 MAP kinase activation and iNOS/NO synthesis by parthenolide in rat primary microglial cells. J Neuroimmunol. 2002;132:18–24.View ArticlePubMedGoogle Scholar
  43. Olajide OA, Bhatia HS, de Oliveira ACP, Wright CW, Fiebich BL. Inhibition of neuroinflammation in LPS-activated microglia by cryptolepine. Evid-Based Complement Altern Med ECAM. 2013;2013:459723.Google Scholar
  44. Baeuerle PA, Baltimore D. NF-kappa B: ten years after. Cell. 1996;87:13–20.View ArticlePubMedGoogle Scholar
  45. Kanarek N, Ben-Neriah Y. Regulation of NF-kB by ubiquitination and degradation of the IkBs. Immunol Rev. 2012;246:77–94.View ArticlePubMedGoogle Scholar
  46. Choi SP, Kim SP, Kang MY, Nam SH, Friedman M. Protective effects of black rice bran against chemically-induced inflammation of mouse skin. J Agric Food Chem. 2010;58:10007–15.View ArticlePubMedGoogle Scholar
  47. Hernández-Aguilera A, Rull A, Rodríguez-Gallego E, Riera-Borrull M, Luciano-Mateo F, Camps J, et al. Mitochondrial dysfunction: a basic mechanism in inflammation-related non-communicable diseases and therapeutic opportunities. Mediators Inflamm. 2013;2013:135698.View ArticlePubMedPubMed CentralGoogle Scholar
  48. Revilla E, Santa-María C, Miramontes E, Candiracci M, Rodríguez-Morgado B, Carballo M, et al. Antiproliferative and immunoactivatory ability of an enzymatic extract from rice bran. Food Chem. 2013;136:526–31.View ArticlePubMedGoogle Scholar
  49. Okai Y, Okada T, Higashi-Okai K, Kasahara E, Inoue M, Yamashita U. Immunomodulating activities in bran extracts of Japanese red, black and brown rices. J UOEH. 2009;31:231–42.PubMedGoogle Scholar
  50. Ren Z, Pae M, Dao MC, Smith D, Meydani SN, Wu D. Dietary supplementation with tocotrienols enhances immune function in C57BL/6 mice. J Nutr. 2010;140:1335–41.View ArticlePubMedGoogle Scholar
  51. Montine TJ, Montine KS, McMahan W, Markesbery WR, Quinn JF, Morrow JD. F2-isoprostanes in Alzheimer and other neurodegenerative diseases. Antioxid Redox Signal. 2005;7:269–75.View ArticlePubMedGoogle Scholar
  52. Montine TJ, Beal MF, Cudkowicz ME, O’Donnell H, Margolin RA, McFarland L, et al. Increased CSF F2-isoprostane concentration in probable AD. Neurology. 1999;52:562–5.View ArticlePubMedGoogle Scholar
  53. Candelario-Jalil E, de Oliveira ACP, Gräf S, Bhatia HS, Hüll M, Muñoz E, et al. Resveratrol potently reduces prostaglandin E2 production and free radical formation in lipopolysaccharide-activated primary rat microglia. J Neuroinflammation. 2007;4:25.View ArticlePubMedPubMed CentralGoogle Scholar
  54. Roschek B, Fink RC, Li D, McMichael M, Tower CM, Smith RD, et al. Pro-inflammatory enzymes, cyclooxygenase 1, cyclooxygenase 2, and 5-lipooxygenase, inhibited by stabilized rice bran extracts. J Med Food. 2009;12:615–23.View ArticlePubMedGoogle Scholar
  55. Egger T, Schuligoi R, Wintersperger A, Amann R, Malle E, Sattler W. Vitamin E (alpha-tocopherol) attenuates cyclo-oxygenase 2 transcription and synthesis in immortalized murine BV-2 microglia. Biochem J. 2003;370:459–67.View ArticlePubMedPubMed CentralGoogle Scholar
  56. Bales KR, Du Y, Dodel RC, Yan GM, Hamilton-Byrd E, Paul SM. The NF-kappaB/Rel family of proteins mediates Abeta-induced neurotoxicity and glial activation. Brain Res Mol Brain Res. 1998;57:63–72.View ArticlePubMedGoogle Scholar
  57. Baldwin AS. The NF-kappa B and I kappa B proteins: new discoveries and insights. Annu Rev Immunol. 1996;14:649–83.View ArticlePubMedGoogle Scholar
  58. Hagl S, Kocher A, Schiborr C, Eckert SH, Ciobanu I, Birringer M, et al. Rice bran extract protects from mitochondrial dysfunction in guinea pig brains. Pharmacol Res. 2013;76:17–27.View ArticlePubMedGoogle Scholar
  59. Sen CK, Khanna S, Rink C, Roy S. Tocotrienols: the emerging face of natural vitamin E. Vitam Horm. 2007;76:203–61.View ArticlePubMedPubMed CentralGoogle Scholar
  60. Bazinet RP, Layé S. Polyunsaturated fatty acids and their metabolites in brain function and disease. Nat Rev Neurosci. 2014;15:771–85.View ArticlePubMedGoogle Scholar


© The Author(s). 2016